Gemifloxacin for the management of community-acquired respiratory tract infections

Journal of Chemotherapy

Volumn 18, Issue 6, 2006, Pages 582-588

  Blondeau, J M ^a,b   Tillotson, G ^c,d   Deangelis, J ^d  

^a ROYAL UNIVERSITY HOSPITAL   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c Replidyne Inc   (United States)

^d Oscient Pharmaceuticals   (United States)

Author keywords

Community respiratory tract infections; Gemifloxacin; Health economics

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BETA LACTAM; CEFTRIAXONE; CEFUROXIME AXETIL; CEPHALOSPORIN; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; TROVAFLOXACIN; ANTIINFECTIVE AGENT; NAPHTHYRIDINE DERIVATIVE; QUINOLONE DERIVATIVE;

ABDOMINAL PAIN; AREA UNDER THE CURVE; CHRONIC BRONCHITIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIZZINESS; DRUG EFFECT; DRUG TOLERABILITY; HEADACHE; HUMAN; IN VITRO STUDY; LOWER RESPIRATORY TRACT INFECTION; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; RASH; REVIEW; STREPTOCOCCUS PNEUMONIAE; TASTE DISORDER; TREATMENT OUTCOME; VOMITING; ANTIBIOTIC RESISTANCE; COMMUNICABLE DISEASE; COST BENEFIT ANALYSIS; ECONOMICS; MICROBIOLOGY; RESPIRATORY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; COST-BENEFIT ANALYSIS; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; NAPHTHYRIDINES; RESPIRATORY TRACT INFECTIONS; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 33846023020     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2006.18.6.582     Document Type: Review

References (48)

1. Minino AM, Arias E, Kochanek KD, et al. Deaths: Final Data for 2000. Natl Vital Stat Rep 2002; 50(15).
2. Mannino DM, Homa DM, Akinbami LJ, et al. Chronic obstructive pulmonary disease surveillance - United States, 1971-2000. Respir Care 2002; 47:1184-1189.
3. Hall MJ, Owings MF. Advanced data from vital and health statistics. Hyattsville, MD: National Center for Health Statistics; 2002 June 19. Report No.: 329.
4. Mandell LA, Niederman MS. Antimicrobial treatment of community-acquired pneumonia in adults: a conference report. The Canadian Community-Acquired Pneumonia Consensus Conference Group. Can J Infect Dis 1993;4:25-8.
5. Niederman MS, McCombs JS, Unger AN, et al. Treatment cost of acute exacerbations of chronic bronchitis. Clin Ther 1999; 21:576-591.
6. O'Brien JA, Patrick AR, Caro JJ. Community acquired pneumonia: costs of managing CAP are double for elderly patients. Drug Benefit Trends 2003:32-47.
7. Jokinen C, Heiskanen L, Jouvonen H, et al. Microbial etiology of community-acquired pneumonia in the adult population of 4 municipalities in eastern Finland. Clin Infect Dis 2001; 32:1141-1154.
8. Ruiz M, Ewig S, Marcos M, et al. Etiology of community-acquired pneumonia: impact of age, comorbidity and severity. Am J Respir Clin Care Med 1999; 160:397-405.
9. Farr BM, Woodhead MA, MacFarlane JT, et al. Risk factors for community-acquired pneumonia diagnosed by general practitioners in the community. Resp Med 2000; 94:422-427.
10. Felmingham D, Farrell DJ, Reinert R, Morrissey I. Antibacterial resistance among children with community-acquired respiratory tract infections (PROTEKT 1999-2000). J Infect 2004; 48:39-55.
11. Doern GV, Brown SD. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01. J Infect 2004; 48(1):56-65.
12. Jacobs MR, Felmingham D, Appelbaum PC, Gruneberg RN, The Alexander Project Group. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003; 52(2):229-246.
13. Lim S, Bast D, McGeer A, de Azavedo J, Low DE. Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance. Emerg Infect Dis 2003; 9(7):833-837.
14. Pletz MWR, McGee L, Jorgenson J, et al. Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for the clonal spread and the impact of conjugate pneumococcal vaccine. Antimicrob Agents Chemother 2004; 48:3491-3497.
15. Doern GV, Richter SS, Miller A, et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes? Clin Infect Dis 2005; 41:139-148.
16. Blondeau JM, Missaghi B. Gemifloxacin: a new fluoroquinolone. Expert Opin Pharmacother 2004; 5(5):1117-1152.
17. Hansen G, Metzler KL, Drlica K, Blondeau JM. Mutant prevention concentration of gemifloxacin for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2003; 47(1):440-441.
18. Jacobs MR, Felmingham D, Appelbaum PC, Gruneberg RN, The Alexander Project Group. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003; 52(2):229-246.
19. Heaton VJ, Ambler J, Fisher LM. Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro. Antimicrob Agents Chemother 2000; 44(11):3112-3117.
20. Hooper DC. Mechanisms of fluoroquinolone resistance. Drug Resistance Updates 1999; 2:38-55.
21. Fisher LM, Gould KA, Pan X-S, Patel S, Heaton VJ. Analysis of dual active fluoroquinolones in Streptococcus pneumoniae. J Antimicrob Chemother 2003; 52:312-316.
22. Gillespie SH, Voelker LL, Dickens A. Evolutionary barriers to quinolone resistance in Streptococcus pneumoniae. Microbial Drug Resistance 2002; 8(2):79-84.
23. Chen DK, McGeer A, De Azavedo J, Low DE, The Canadian Bacterial Surveillance Network. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999; 341:233-239.
24. Perez-Trallero E, Garcia-Rey C, Martin-Sanchez AM, et al. Activities of six different quinolones against clinical respiratory isolates of Streptococcus pneumoniae with reduced susceptibility to ciprofloxacin in Spain. Antimicrob Agents Chemother 2002; 46(8):2665-2667.
25. Rittenhouse S, Donald B, Niconovich N, et al. Effect of gemifloxacin and comparator quinolones on the development of in vitro bacterial resistance. J Antimicrob Chemother 1999; 44 (Suppl. A.) Abstract #P486, Page 147.
26. Gillespie SH, Voelker LL, Dickens A. Evolutionary barriers to quinolone resistance in Streptococcus pneumoniae. Microbial Drug Resistance 2002; 8(2):79-84.
27. Dong Y, Zhao X, Domagala J, Drlica K. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob Agents Chemother 1999; 43:1756-1758.
28. Blondeau JM, Hansen G, Metzler KL, Hedlin P. The role of PK/PD parameters to avoid selection and increase of resistance: mutant prevention concentration. J Chemother 2004; 16 (Suppl. 3):1-19.
29. Blondeau J, Zhao X, Hansen GT, Drlica K. Mutant prevention concentrations (MPC) for fluoroquinolones with clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2001; 45:433-438.
30. Blondeau JM, Borsos S, Hesje C, Blondeau LD. Determination of the mutant prevention concentration and minimal inhibitory concentration of gemifloxacin against penicillin susceptible and resistant clinical isolates of Streptococcus pneumoniae. In: 15th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 2005 April 2-5; Copenhagen; 2005.
31. Blondeau JM, Hansen G, Metzler KL, Borsos S, Chau J. Optimal killing of Streptococcus pneumoniae by gemifloxacin, levofloxacin and moxifloxacin. In: Gillespie SH, Tillotson GS, eds. Novel Perspectives in Antibacterial Action. London: Royal Society of Medicine Press Limited; 2002:15-26.
32. Oscient Pharmaceuticals. Gemifloxacin (FACTIVE), Prescribing Information. Waltham, MA, USA; 2004.
33. Gee T, Andrews JM, Ashby JP, Marshall G, Wise R. Pharmacokinetics and tissue penetration of gemifloxacin following a single oral dose. J Antimicrob Chemother 2001; 47:431-434.
34. Lode H, File Jr. TM, Mandell LA, et al. Oral gemfloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability. Clin Ther 2002; 24(11):1915-1936.
35. File Jr. TM, Schlemmer B, Garau J. et al. Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin. J Antimicrob Chemother 2001; 48:67-74.
36. Leophonte P, File Jr. TM, Feldman C. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Resp Med 2004; 98:708-720.
37. Wilson R, Schentag JJ, Ball P, Mandell LA, 068 Study Group. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Ther 2002; 24(4):639-652.
38. Sethi S, Fogarty C, Fulambarker A. A randomized, double-blind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis. Resp Med 2004; 98(8):697-707.
39. File Jr. TM, Sclemmer B, Garau J, et al. Gemifloxacin versus amoxicillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis. J Chemother 2000; 12:314-325
40. Ball P, Wilson R, Mandell LA, et al. Efficacy of gemifloxacin in acute exacerbations of chronic bronchitis: a randomized, double-blind comparison with trovafloxacin. J Chemother 2001; 13(3):288-298.
41. File TM, Mandell LA, Bunt T, et al. 5-Day, short-course gemifloxacin therapy to treat community-acquired pneumonia (CAP). September 17-19, 2005, Second International Conference on Community Acquired Pneumonia, Montréal, Canada.
42. Wilson R, Langan C, Ball P, et al. Oral gemifloxacin once daily for 5 days compared with sequential therapy with i.v. ceftriaxone/oral cefuroxime (maximum of 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitis. Respir Med 2003; 97:242-249.
43. Ball P. Adverse drug reactions: implications for the development of fluoroquinolones. J Antimicrob Chemother 2003; 51(Suppl.):21-27.
44. Birnbaum HG, Morley M, Greenberg PE, Colice GL. Economic burden of respiratory infections in an employed population. Chest 2002; 122:603-611.
45. Halpern MT, Palmer CS, Zodet M, Kirsch J. Cost-effectiveness of gemifloxacin: results from the GLOBE Study. Am J Health Syst Pharm 2002; 59(14):1357-1365.
46. Halpern MT, Higashi MK, Bakst AW, Schmier JK. The economic impact of acute exacerbations of chronic bronchitis in the United States and Canada: a literature review. J Managed Care Pharmacy 2003; 9(4):353-359.
47. Blondeau JM, Hansen G, Zhao X, Drlica K. Mutation prevention concentration (MPC) for gemifloxacin against clinical isolates of Streptococcus pneumoniae (SP) with high MPC values to levofloxacin. In: 22nd International Congress of Chemotherapy; 2001 June 30-July 3; Amsterdam, The Netherlands; 2001.
48. Zhanel GG, Noreddin AM. Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections. Curr Opin Pharmacol 2001; 1: 459-463.